Tumor-associated glycoprotein 72
Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary,[1][2][3] breast, colon,[4] lung, and pancreatic cancers.[5][6] It is a mucin-like molecule with a molar mass of over 1000 kDa.[7]
TAG-72 is a tumor marker measured with radioimmunoassays like CA 72-4, which uses the monoclonal antibodies indium (111In) satumomab pendetide and iodine (125I) minretumomab.[8][9][10][11][12] This assay has a good specificity for gastric cancer, with a correlation to the neoplasia's extension. It is used to identify relapses of the disease and to follow up the treatment.
TAG-72 is also the target of the anti-cancer drugs anatumomab mafenatox and minretumomab.
References
[edit]- ^ Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, Smith L, Davis JS, Remmenga SW, Batra SK. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett. 2007 Jun 28;251(2):247-57. doi: 10.1016/j.canlet.2006.11.025. Epub 2007 Jan 8. PMID: 17210225.
- ^ Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ. Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. PMID: 30510550; PMCID: PMC6254427.
- ^ Shu R, Evtimov VJ, Hammett MV, Nguyen NN, Zhuang J, Hudson PJ, Howard MC, Pupovac A, Trounson AO, Boyd RL. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. Mol Ther Oncolytics. 2021 Jan 16;20:325-341. doi: 10.1016/j.omto.2021.01.002. PMID: 33614914; PMCID: PMC7868933.
- ^ Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. PMID: 28344808; PMCID: PMC5360066.
- ^ TAG-72 antigen entry in the public domain NCI Dictionary of Cancer Terms
- ^ Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J. (2012). "Antibody therapy of cancer". Nature Reviews Cancer. 12 (4): 278–87. doi:10.1038/nrc3236. PMID 22437872. S2CID 205469234.
- ^ Sheer, Donald G.; Schlom, J; Cooper, HL (1988). "Purification and Composition of the Human Tumor-associated Glycoprotein (TAG-72) Defined by Monoclonal Antibodies CC49 and B72.3". Cancer Research. 48 (23): 6811–6818. PMID 3180090.
- ^ Louhimo J, Alfthan H, Stenman UH, Haglund C (2004). "Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer". Oncology. 66 (2): 126–31. doi:10.1159/000077438. PMID 15138364. S2CID 25798287.
- ^ Louhimo J, Carpelan-Holmström M, Alfthan H, Stenman UH, Järvinen HJ, Haglund C (October 2002). "Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer". Int. J. Cancer. 101 (6): 545–8. doi:10.1002/ijc.90009. PMID 12237895.
- ^ Louhimo J, Kokkola A, Alfthan H, Stenman UH, Haglund C (October 2004). "Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer". Int. J. Cancer. 111 (6): 929–33. doi:10.1002/ijc.20321. PMID 15300805. S2CID 24698852.
- ^ Mattar R, Alves de Andrade CR, DiFavero GM, Gama-Rodrigues JJ, Laudanna AA (2002). "Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer". Rev Hosp Clin Fac Med Sao Paulo. 57 (3): 89–92. doi:10.1590/s0041-87812002000300001. PMID 12118264.
- ^ Guadagni F, Roselli M, Cosimelli M, et al. (November 1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Res. 56 (22): 5293–8. PMID 8912871.
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
 | This oncology article is a stub. You can help Wikipedia by expanding it. |